If two or more antidepressants haven't helped your depression, you may have TRD. Ketamine therapy is the most promising treatment option in decades. Here's the complete guide.
Treatment-resistant depression (TRD) is clinically defined as major depressive disorder that has not responded adequately to at least two different antidepressant medications, each taken at an adequate dose for an adequate duration (typically 6-8 weeks). By this definition, approximately 30% of people with depression have treatment-resistant depression.
If you've tried SSRIs like Prozac or Zoloft, SNRIs like Effexor or Cymbalta, or other antidepressant classes without meaningful relief, you may meet the criteria for TRD. This isn't a personal failure — it's a neurobiological reality. Your brain's depression circuitry may not respond to the serotonin and norepinephrine pathways that traditional antidepressants target.
TRD is among the most disabling medical conditions. Patients with TRD experience longer depressive episodes, higher rates of hospitalization, greater functional impairment, and significantly elevated suicide risk compared to patients whose depression responds to standard treatment. The societal burden is enormous: TRD accounts for a disproportionate share of depression-related healthcare costs, estimated at over $43 billion annually in the United States alone.
You likely have treatment-resistant depression if you've tried two or more antidepressant medications at adequate doses for adequate time periods without significant improvement. Other indicators include: persistent depressive symptoms despite medication compliance, frequent medication switches, augmentation strategies (adding a second medication), or hospitalization for depression. A formal TRD diagnosis is made by your psychiatrist or prescribing physician.
Traditional antidepressants primarily target the monoamine neurotransmitter systems — serotonin, norepinephrine, and dopamine. They work by increasing the availability of these chemicals in the brain. For many patients, this mechanism produces meaningful relief.
But depression is not a single disease with a single cause. Emerging research shows that TRD often involves dysfunction in the glutamate system, neuroinflammation, impaired neuroplasticity, and disrupted neural connectivity. None of these mechanisms are addressed by traditional antidepressants. This is why ketamine — which works through an entirely different pathway — can succeed where SSRIs and SNRIs fail.
Ketamine's antidepressant mechanism is fundamentally different from any traditional medication. Rather than slowly modulating serotonin over weeks, ketamine acts on the glutamate system — the brain's primary excitatory neurotransmitter — to produce rapid and often dramatic antidepressant effects.
Ketamine blocks NMDA receptors (a type of glutamate receptor), which triggers a cascade of downstream effects. This blockade leads to increased release of glutamate, which activates AMPA receptors. The AMPA activation stimulates the production of brain-derived neurotrophic factor (BDNF), a protein critical for neuroplasticity — the brain's ability to form new neural connections.
In depressed brains, neural connections in key regions (particularly the prefrontal cortex and hippocampus) are weakened or lost. Ketamine essentially helps rebuild these connections, sometimes within hours. This is why patients often report feeling better within hours to days of their first dose, compared to the 4-8 week wait typical of SSRIs.
The speed of ketamine's effect is perhaps its most remarkable feature. In clinical trials, significant antidepressant effects have been observed within 4 hours of administration, with peak effects typically occurring at 24 hours. For patients who have waited months or years for relief from traditional medications, this rapid response can be transformative.
Beyond the immediate mood improvement, ketamine creates what clinicians call a "neuroplasticity window" — a period of enhanced neural flexibility that can last days to weeks after each dose. During this window, the brain is more receptive to forming new patterns of thought and behavior. This is why many psychiatrists and therapists recommend combining ketamine therapy with psychotherapy for maximum benefit. The medication opens the door; therapy helps you walk through it.
Ready to explore ketamine therapy for TRD?
Free Consultation at Kalm Health →Ketamine for depression is not experimental — it is supported by a robust and growing evidence base from major research institutions worldwide.
NEJM 2023 — Ketamine vs. ECT: A landmark randomized controlled trial published in the New England Journal of Medicine compared ketamine to electroconvulsive therapy (ECT), the previous gold standard for TRD. Ketamine achieved a 55.4% response rate compared to 41.2% for ECT, with fewer cognitive side effects. This trial fundamentally shifted the treatment landscape for TRD.
Nature Medicine 2024 — Oral Ketamine Sustained Efficacy: A phase III clinical trial published in Nature Medicine demonstrated that oral ketamine maintained its antidepressant efficacy over 12 weeks of treatment. This addressed the critical question of whether ketamine's benefits are sustained with ongoing use — they are.
Meta-Analysis Evidence: A 2023 meta-analysis pooling data from over 30 randomized controlled trials found that ketamine produced statistically significant antidepressant effects compared to placebo, with effect sizes classified as "large" by standard measures. The number needed to treat (NNT) was approximately 3, meaning one in every three TRD patients who tries ketamine experiences meaningful improvement.
Ketamine for TRD is supported by multiple randomized controlled trials, published in the world's most prestigious medical journals. It is not alternative medicine, not experimental, and not fringe. It is an evidence-based treatment option that outperforms ECT in head-to-head trials and has been validated for sustained use.
The FDA has approved esketamine (Spravato), a nasal spray form of ketamine's S-enantiomer, specifically for treatment-resistant depression. While generic racemic ketamine is prescribed off-label for depression, it is prescribed by licensed physicians based on the same evidence base and is widely accepted in psychiatric practice.
There are two primary ways to receive ketamine therapy: intravenous (IV) infusions administered in a clinic, or sublingual (oral) ketamine taken at home. Both are effective, but they differ significantly in cost, convenience, and accessibility.
For most TRD patients, at-home sublingual ketamine offers the best balance of efficacy, affordability, and sustainability. IV infusions can be valuable for acute crisis intervention, but the cost makes them impractical for the long-term maintenance that TRD typically requires.
Kalm Health is the most affordable at-home option at $124/month with no dose cap, making long-term TRD treatment financially sustainable.
Most at-home ketamine providers evaluate patients based on the following criteria:
Ketamine therapy is contraindicated in patients with active psychotic disorders (schizophrenia, schizoaffective disorder), uncontrolled hypertension, active substance abuse, pregnancy, or certain cardiovascular conditions. Always disclose your complete medical history to your prescribing physician. A responsible provider will decline patients for whom ketamine poses unacceptable risk.
Treatment begins with a medical consultation, typically conducted via telehealth. A physician reviews your psychiatric history, current medications, medical conditions, and treatment goals. At Kalm Health, this consultation is completely free. Other providers charge $100-$250 for this initial evaluation.
If approved, your prescription is filled by a licensed compounding pharmacy and shipped directly to your home. Most patients receive their medication within 3-7 days. The medication arrives as sublingual lozenges (troches) that you dissolve under your tongue.
For your first dose, you'll want a calm, quiet environment. Have someone present if possible (required by some providers). The lozenge dissolves over 10-15 minutes. Effects typically begin within 15-30 minutes and may include a dreamlike or dissociative state, altered perception of time, mild euphoria, and a sense of detachment from negative thought patterns. These effects typically subside within 1-2 hours.
Most patients take ketamine 2-3 times per week initially, then taper to a maintenance schedule based on their response. Your provider adjusts dosing based on your feedback and symptom tracking. With a no-cap provider like Kalm Health, your dose can be increased as clinically needed without hitting an artificial limit.
Dosing is one of the most important — and most misunderstood — aspects of ketamine therapy. Getting the dose right can mean the difference between life-changing relief and no effect at all.
Sublingual ketamine has approximately 25-30% bioavailability, meaning only a quarter to a third of the stated dose actually reaches your bloodstream. A 100mg lozenge delivers roughly 25-30mg of active ketamine. This is why sublingual doses appear much higher than IV doses — the delivery method requires higher nominal doses to achieve therapeutic blood levels.
Optimal ketamine dosing varies enormously between individuals. Body weight, metabolism, liver function, prior ketamine exposure, concurrent medications, and the severity of depression all influence what dose will be effective. There is no single "right dose" that works for everyone.
Some providers (notably Joyous) cap their maximum dose at 120mg. For a portion of patients, this ceiling is sufficient. But for many TRD patients, particularly those with severe or long-standing depression, doses above this threshold may be necessary for adequate response. Research consistently shows that higher doses tend to produce better outcomes for TRD specifically.
When a provider caps your dose at an arbitrary level, they are making a business decision that may conflict with your clinical needs. Providers like Kalm Health do not impose hard dose caps, allowing your physician to prescribe what is clinically appropriate for your situation.
Early dose-response studies found increased antidepressant response with higher ketamine doses. The 2023 NEJM trial that compared ketamine favorably to ECT used doses well above the 120mg ceiling imposed by some at-home providers. The evidence supports individualized, flexible dosing for TRD — not one-size-fits-all protocols.
Not all at-home ketamine providers are equal, especially for TRD patients who need long-term treatment flexibility. Here's how the major providers compare on the factors that matter most for treatment-resistant depression.
| Provider | Monthly Cost | Dose Cap | Consultation | TRD Suitability |
|---|---|---|---|---|
| Kalm Health | $124/mo | No cap | Free | Excellent — flexible dosing, TRD focus |
| Joyous | $129/mo | 120mg max | Included | Poor — dose cap limits TRD treatment |
| Mindbloom | $258-318/mo | Varies | $250 | Good — higher doses, but expensive |
| Nue Life | $233+/mo | Varies | Included | Moderate — good platform, high cost |
| Better U | $150/mo | Varies | $100 | Moderate — mid-range option |
For TRD patients specifically, the combination of no dose cap, lowest price, and free consultation makes Kalm Health the strongest option. When your depression hasn't responded to other treatments, you need a provider that won't limit your care based on arbitrary policy constraints.
Living with treatment-resistant depression? You don't have to keep trying the same medications that haven't worked.
Start Your Free Consultation →Cost is a major factor for TRD patients, many of whom have already spent thousands on medications, therapy, and hospitalizations. Here's a realistic breakdown of what ketamine therapy costs across different delivery methods.
Most at-home ketamine therapy is not covered by insurance, but is HSA/FSA eligible. Some patients have successfully obtained partial reimbursement by submitting superbills to their insurance. At Kalm Health, all major credit cards and HSA/FSA cards are accepted.
If you've been struggling with treatment-resistant depression and want to explore ketamine therapy, here's a step-by-step guide to getting started with at-home treatment.
Visit kalmhealth.org and complete the intake questionnaire. It takes about 5 minutes and covers your psychiatric history, current medications, and treatment goals. A physician reviews your information and determines if ketamine therapy is appropriate for you.
Your physician conducts a telehealth evaluation to discuss your history in detail. This is a real conversation with a real doctor — not an automated screening. They'll answer your questions and explain what to expect.
If approved, your sublingual ketamine prescription ships directly to your door within 3-5 days. You receive detailed instructions for your first session, including dosing, environment preparation, and what to expect.
Your provider monitors your progress through regular check-ins. Doses are adjusted based on your response — up or down, with no artificial cap. Your treatment plan evolves with your needs.
If antidepressants haven't worked, ketamine offers a different approach backed by rigorous clinical evidence. Free consultation. $124/month. No dose cap. All 50 states.
Start Your Free Consultation at Kalm Health →Many patients notice improvement within hours to days of their first dose. Clinical trials show significant antidepressant effects within 24 hours. However, sustained benefits typically require ongoing treatment over weeks to months.
At therapeutic doses prescribed by a physician, the risk of addiction is low. Ketamine can be psychologically habit-forming in recreational contexts, but medical use under supervision involves lower doses, less frequent administration, and clinical monitoring. Your provider screens for substance use risk factors before prescribing.
In most cases, yes. Ketamine works through a different mechanism (glutamate) than SSRIs and SNRIs (serotonin/norepinephrine). Your prescribing physician will review your medication list for any specific interactions. Some patients eventually taper other antidepressants with their psychiatrist's guidance as ketamine proves effective.
Common side effects during a ketamine session include dissociation (feeling detached from your body), nausea, dizziness, increased blood pressure, and vivid perceptual changes. These effects are temporary and typically resolve within 1-2 hours. Long-term side effects are minimal at therapeutic doses, though bladder issues have been reported with chronic recreational use at much higher doses.
This varies by individual. Some patients use ketamine for several months and then taper off with sustained improvement. Others find that ongoing maintenance dosing (reduced frequency) is necessary. Your provider will work with you to find the right long-term plan.
Kalm Health offers the lowest price ($124/month), no dose cap, free consultation, all 50 states, direct physician access, and a dedicated higher-dose plan for patients above 1200mg/month. For TRD patients who need long-term treatment flexibility, these factors are critical.